Paclitaxel and cisplatin combined with anlotinib as first line regimen for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicentre open-label phase II clinical trial

被引：0
|
作者：
Wang, J-S. [1 ]
Wu, T. [1 ]
Hong, Y-G. [1 ]
Guo, Y-Z. [2 ]
Luo, S-X. [3 ]
Li, N. [3 ]
Cheng, Y-F. [4 ]
Li, B-S. [5 ]
机构：
[1] Anyang Tumour Hosp, Dept Med Oncol, Anyang, Peoples R China
[2] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Med Oncol, Luoyang, Peoples R China
[3] Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[4] Shandong Univ, Qilu Hosp, Dept Radiat Oncol, Jinan, Peoples R China
[5] Shandong Canc Hosp, Dept Radiat Oncol, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1954
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1448P
引用
收藏
页码：S910 / S911
页数：2
相关论文
共 50 条
  • [21] Anlotinib combined with paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC).
    Jiang, Gongqian
    Wang, Guolei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 409 - 409
  • [22] Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: A single-arm phase II clinical trial
    Liu, T.
    Xiao, D.
    Li, Q.
    Chen, Y.
    Tian, J.
    Lin, Z.
    Ding, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S35 - S35
  • [23] Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study.
    Wang, Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Wang Junsheng
    Wu Tao
    Hong Yonggui
    Meng Xiangrui
    Ren Zhonghai
    Guo Yanzhen
    Yang Xiuli
    Shi Pei
    Yang Jiamei
    Fan Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [25] First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multi-center phase II trial.
    Wang, Junsheng
    Li, Ning
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial
    Gong, Lei
    Yang, Yueyang
    Zhang, Hongdian
    Qiao, Yufeng
    Wang, Haitong
    Ren, Peng
    Tang, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Qi Yu
    Meng Xiangrui
    Fan Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [28] Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS)
    Jiang, Youhua
    Qiu, Guoqin
    Li, Jianqiang
    Wang, Jiangfeng
    Wang, Changchun
    Wu, Jie
    Cheng, Lei
    Zheng, Yuanda
    Ruan, Rongwei
    Song, Ge
    Ye, Xuemei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
    Wang, X.
    Ma, J.
    Zhang, J.
    Yang, Y.
    Zheng, D.
    Liang, H.
    Zhang, L.
    Xin, Y.
    Ling, X.
    Fang, C.
    Jiang, H.
    Zheng, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
  • [30] CAMRELIZUMAB COMBINED WITH PACLITAXEL AND NEDAPLATIN IN THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM, EXPLORATORY RESEARCH
    Ma, Jianqun
    Zhang, Jinfeng
    Yang, Yingnan
    Zheng, Dayong
    Wang, Xiaoyuan
    Liang, Hao
    Zhang, Luquan
    Xin, Yanzhong
    Ling, Xiaodong
    Fang, Chengyuan
    Jiang, Hao
    Zheng, Wei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A437 - A437
12345